Dyax Corp.
55 Network Drive
Burlington
Massachusetts
01803
United States
Tel: 617-225-2500
Fax: 617-225-2501
Website: http://www.dyax.com/
Email: ir@dyax.com
About Dyax Corp.
Founded in 1995, Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company’s key areas of focus are the KALBITOR® (ecallantide) business and the Angioedema Portfolio, as well as the Licensing and Funded Research Program (LFRP). Dyax discovered and developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside of the United States, the Company has established partnerships to obtain regulatory approval for and commercialize KALBITOR in certain markets and is evaluating opportunities in others. Currently, Dyax has collaboration agreements for regions including Europe, Japan, Russia, the Middle East, Australia and New Zealand. Dyax is also exploring other potential indications for KALBITOR, either alone or through collaborations.The Company is expanding its portfolio for the treatment of angioedemas by identifying diagnostic strategies to assist in the differentiation between histamine-mediated and plasma kallikrein (bradykinin) mediated (PKM) angioedema, and developing a fully human monoclonal antibody inhibitor of plasma kallikrein, DX-2930, which could be a candidate to prophylactically treat PKM angioedemas. KALBITOR and DX-2930 were identified using Dyax’s patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 11 product candidates in various stages of clinical development, including three in Phase 3 trials.
Dyax is headquartered in Burlington, Massachusetts. For online information about Dyax Corp., please visit www.dyax.com.
338 articles about Dyax Corp.
-
The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL), basically a rejection, to Netherlands-based Pharming Group for its supplemental Biologics License Application (sBLA) for Ruconest.
-
The U.S. Food and Drug Administration (FDA) approved Shire’s Takhzyro (lanadelumab-flyo) injection to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. The drug was accepted while under priority review.
-
Shire plc snagged approval from the U.S. Food and Drug Administration for Takhzyro (lanadelumab-flyo), a prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years of age and older.
-
Shire's $6.5 Billion Dyax Bet Pays Off as Lanadelumab Wows in Phase III Study
5/18/2017
-
Shire Remains Tight-Lipped on Status of Facilities, Employees Inherited from Newly-Acquired Dyax
1/27/2016
-
Shire Completes Acquisition Of Dyax
1/22/2016
-
Biotechs Like Dyax, Sarepta are Amongst Massachusetts' Top Performing Stocks for 2015
12/15/2015
-
Dyax Sets January 21, 2016 As Date Of Special Stockholder Meeting To Vote On Its Proposed Acquisition By Shire
12/11/2015
-
Dyax Sets January 21, 2016 As Date Of Special Stockholder Meeting To Vote On Its Proposed Acquisition By Shire
12/11/2015
-
Dyax Presents DX-4012 Data At The 2015 American Society of Hematology Annual Meeting
12/7/2015
-
Dyax Announces Early Termination Of Hart-Scott-Rodino Waiting Period
12/3/2015
-
Dyax Recognized As A “Top Place To Work” By The Boston Globe For Second Year In A Row
11/17/2015
-
Dyax Presents Phase 1b DX-2930 Data At American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting
11/10/2015
-
Shire's New Buy Dyax is Another Biotech with Ties to Genzyme
11/4/2015
-
Still Yearning for Baxalta, Shire Snaps Up Dyax in $5.9 Billion Deal
11/3/2015
-
Dyax Announces Cancellation Of Research And Development Day
11/2/2015
-
Dyax Corp. Announces Third Quarter 2015 Financial Results
10/29/2015
-
Dyax Corp. To Webcast 2015 Research And Development Day
10/27/2015
-
Dyax Corp. To Review Third Quarter 2015 Financial Results At Research And Development Day
10/27/2015
-
Dyax Corp. To Host Third Quarter 2015 Financial Results Call And Webcast
10/14/2015